Zealand Pharma AS (CHIX:ZEALC) Cyclically Adjusted Book per Share: kr54.74 (As of Mar. 2026)


CHIX:ZEALC Zealand Pharma AS CHIX:ZEALC
58 GF Score
Price kr278.70
GF Value kr11,527.25
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Zealand Pharma AS Cyclically Adjusted Book per Share?

Zealand Pharma AS CHIX:ZEALC 58 Cyclically Adjusted Book per Share is kr54.74 as of Mar. 2026. GuruFocus rates CHIX:ZEALC with a GF Score™ of 58/100 and a GF Value™ of kr11,527.25 (Possible Value Trap). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Zealand Pharma AS's adjusted book value per share for the three months ended in Mar. 2026 was kr204.769. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is kr54.74 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Zealand Pharma AS's average Cyclically Adjusted Book Growth Rate was 58.40% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 31.80% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 18.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Zealand Pharma AS was 31.80% per year. The lowest was 4.40% per year. And the median was 10.55% per year.

As of today (2026-07-08), Zealand Pharma AS's current stock price is kr278.70. Zealand Pharma AS's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was kr54.74. Zealand Pharma AS's Cyclically Adjusted PB Ratio of today is 5.09.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Zealand Pharma AS was 36.88. The lowest was 3.30. And the median was 10.33.


Zealand Pharma AS  (CHIX:ZEALc) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Zealand Pharma AS's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=278.70/54.74
=5.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Zealand Pharma AS was 36.88. The lowest was 3.30. And the median was 10.33.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Zealand Pharma AS Cyclically Adjusted Book per Share Related Terms


Zealand Pharma AS Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Zealand Pharma AS's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zealand Pharma AS Cyclically Adjusted Book per Share Chart

Zealand Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.98 22.63 22.43 36.61 51.36

Zealand Pharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.80 41.47 44.59 51.36 54.74

CHIX:ZEALC vs VRTX, REGN, ALNY: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Zealand Pharma AS's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zealand Pharma AS Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Zealand Pharma AS's Cyclically Adjusted PB Ratio falls into.


CHIX:ZEALC
58GF Score
Zealand Pharma AS CHIX:ZEALC
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zealand Pharma AS Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zealand Pharma AS's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=204.769/121.6800*121.6800
=204.769

Current CPI (Mar. 2026) = 121.6800.

Zealand Pharma AS Quarterly Data

Book Value per Share CPI Adj_Book
201606 4.486 100.600 5.426
201609 8.535 100.200 10.365
201612 10.876 100.300 13.194
201703 9.875 101.200 11.873
201706 7.085 101.200 8.519
201709 20.824 101.800 24.891
201712 16.772 101.300 20.146
201803 14.243 101.700 17.041
201806 10.305 102.300 12.257
201809 40.422 102.400 48.033
201812 36.334 102.100 43.302
201903 34.316 102.900 40.579
201906 30.449 102.900 36.006
201909 39.362 102.900 46.546
201912 33.168 102.900 39.221
202003 32.948 103.300 38.810
202006 45.299 103.200 53.411
202009 40.035 103.500 47.067
202012 30.887 103.400 36.347
202103 38.522 104.300 44.941
202106 31.848 105.000 36.907
202109 27.471 105.800 31.594
202112 21.469 106.600 24.506
202203 16.422 109.900 18.182
202206 10.951 113.600 11.730
202209 7.913 116.400 8.272
202212 15.852 115.900 16.643
202303 13.004 117.300 13.490
202306 29.649 116.400 30.994
202309 31.163 117.400 32.299
202312 27.285 116.700 28.449
202403 45.555 118.400 46.817
202406 132.485 118.500 136.040
202409 125.740 118.900 128.680
202412 121.964 118.900 124.816
202503 117.529 120.200 118.976
202506 221.773 120.700 223.574
202509 215.724 121.600 215.866
202512 210.045 121.200 210.877
202603 204.769 121.680 204.769

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of kr54.74 mean?
Zealand Pharma AS (CHIX:ZEALC) has a Cyclically Adjusted Book per Share of kr54.74 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Zealand Pharma AS and its competitors.
Is Zealand Pharma AS's Cyclically Adjusted Book per Share too high?
Zealand Pharma AS's current Cyclically Adjusted Book per Share is kr54.74. Overall, Zealand Pharma AS has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's Cyclically Adjusted Book per Share compare to VRTX and REGN?
Zealand Pharma AS's Cyclically Adjusted Book per Share of kr54.74 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Zealand Pharma AS and its competitors. Zealand Pharma AS's current Cyclically Adjusted Book per Share is kr54.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Based on GuruFocus' analysis, Zealand Pharma AS (CHIX:ZEALC) is currently considered Possible Value Trap. The stock's GF Value™ is kr11,527.25, compared to a current price of kr278.70 — trading 97.6% below its estimated fair value. The current Cyclically Adjusted Book per Share is kr54.74. Zealand Pharma AS's overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Zealand Pharma AS (CHIX:ZEALC), the current Cyclically Adjusted Book per Share is kr54.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zealand Pharma AS (CHIX:ZEALC) Overvalued in 2026?

Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued. The current stock price of kr278.70 is trading 97.6% below its estimated GF Value™ of kr11,527.25. GuruFocus considers Zealand Pharma AS to be Possible Value Trap.

Key valuation signals for CHIX:ZEALC:

  • Cyclically Adjusted Book per Share: kr54.74
  • GF Value™: kr11,527.25 vs. price of kr278.70 (97.6% below fair value)
  • GF Score™: 58/100 with 3 warning signs

No single metric tells the full story. See the CHIX:ZEALC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zealand Pharma AS Business Description

Address Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
58GF Score

Get the complete analysis for CHIX:ZEALC

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr278.70
Price
kr11,527.25
GF Value